Relacorilant + Nab-Paclitaxel vs Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer: Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Exposure-Response

February 27, 2026

Colombo et al. • 2026 • ESGO

Phase 3 ROSELLA (GOG-3073, ENGOT-ov72) Trial of Relacorilant + Nab-paclitaxel vs Nab-paclitaxel in Platinum-resistant Ovarian Cancer: Primary Results and Outcomes in Older Patients

November 4, 2025

Olawaiye et al. • 2025 • IGCS

BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers

October 18, 2025

Lorusso et al. • 2025 • ESMO

Phase 3 Results of Relacorilant + Nab-Paclitaxel v Nab-Paclitaxel In Platinum-Resistant Ovarian Cancer (ROSELLA): Secondary Endpoints

June 19, 2025

Lorusso et al. • 2025 • ESMO Gyn

Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer

March 18, 2024

Colombo et al. • 2024 • SGO 2024 Congress